Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
39 Results for "
GMP-AMP
" in MedChemExpress (MCE) Product Catalog:
Products (39)
39 Results for "GMP-AMP" in MCE Product Catalog:
86
86 Publications Verification
Synonyms: RU320521
Target:
Research Areas:
RU.521 (RU320521) is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor and inhibits cGAS-mediated interferon upregulation. RU.521 suppresses dsDNA-activated reporter activity with an IC50 of 0.7 μM. RU.521 reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome (AGS) .
42
42 Cited Publications
Synonyms: 2'-3'-cyclic GMP-AMP
Target:
42
42 Cited Publications
Synonyms: 2'-3'-cyclic GMP-AMP sodium
Target:
27
27 Cited Publications
Synonyms: Cyclic GMP-AMP; 3',3'-cGAMP
Target:
Research Areas:
cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
27
27 Cited Publications
Synonyms: Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium
Category:
Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
27
27 Cited Publications
Cat. No.: HY-110385A
Purity: 95.19%
Synonyms: Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium
Target:
8
8 Cited Publications
Target:
Research Areas:
G150 is a highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with an IC50 of 10.2 nM. G150 represses dsDNA-triggered interferon expression, and G150 can be used for the research of inflammatory .
7
7 Cited Publications
Target:
Research Areas:
G140 is a potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS), with IC50s of 14.0 nM and 442 nM for h-cGAS and m-cGAS, respectively. G140 has anti-inflammatory activity .
3
3 Cited Publications
Target:
Research Areas:
PF-06928215 is a cGAS (cyclic GMP-AMP Synthase) inhibitor with an IC50 of 4.9 μΜ. PF-06928215 has a high binding affinity of 0.2 μM (Kd) .
3
3 Cited Publications
Cat. No.: HY-P72337
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CGAS; D4; Prev. C6orf150; DANGER Family Member 4; Prev. MB21D1; CGAMP Synthase; H-CGAS; Chromosome 6 Open Reading Frame 150; Mab-21 Domain-Containing Protein 1; Protein MB21D1; 2'3'-CGAMP Synthase; Cyclic GMP-AMP Synthase; Mab-21 Domain Containing 1
1
1 Cited Publications
Cat. No.: HY-124700
CAS No.: 1966129-74-7
Research Areas:
LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
1
1 Cited Publications
Target:
Research Areas:
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .
1
Target:
1
1 Cited Publications
Target:
1
1 Cited Publications
Cat. No.: HY-P71597
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CGAS; D4; Prev. C6orf150; DANGER Family Member 4; Prev. MB21D1; CGAMP Synthase; H-CGAS; Chromosome 6 Open Reading Frame 150; Mab-21 Domain-Containing Protein 1; Protein MB21D1; 2'3'-CGAMP Synthase; Cyclic GMP-AMP Synthase; Mab-21 Domain Containing 1
Cat. No.: HY-160546
CAS No.: 2765273-11-6
Target:
Research Areas:
cGAS-IN-2 (compound 109) is a potent inhibitor of Cyclic GMP-AMP Synthase (cGAS), with IC50 of 0.01512 μM for h-cGAS .
Cat. No.: HY-174801
CAS No.: 3117797-30-2
Target:
Research Areas:
XL-3156 is a cGAS inhibitor. XL-3156 occupies both allosteric and orthosteric sites simultaneously, and inhibits the interaction and phase separation between cGAS and DNA by stabilizing the closed conformation of the activation loop. XL-3156 can be used in the research of diseases such as autoimmune diseases and inflammation .
Target:
Research Areas:
cGAS-IN-1 (Compound C20) is a cyclic GMP-AMP synthase (cGAS) inhibitor with IC50s of 2.28 μM (human cGAS, h-cGAS FL) and 1.44 μM (mouse cGAS, m-cGAS CD). cGAS-IN-1 can be used for the studies of autoimmune diseases and chronic inflammation .
Cat. No.: HY-164288
CAS No.: 2287331-29-5
Synonyms: TDI-006570
Target:
Research Areas:
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
Cat. No.: HY-170362
CAS No.: 2987886-49-5
Target:
Research Areas:
cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models .
orally active, THP-1, C57Bl/6 mouse, orally active
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
